CD274 and neoplasm: In addition to analysis by PD-L1 tumor expression (Table 4), IMmotion150, IMmotion151 and JAVELIN Renal 101 trials conducted exploratory biomarker analyses to investigate the role of angiogenesis and T-effector gene expression signatures (GEs) in therapeutic outcomes.